Stock listing
OTC:PGBIF PegBio Co., Ltd. Stock
US listing (OTC) of PegBio Co., Ltd. · home listing HKEX:2565
Follow PegBio Co., Ltd. into a list and get an email when it puts out news.
Home listing price · HKEX:2565
$2.23 HKD -0.19 (-8.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2565
- Day range
- $2.17 – $2.45 HKDNov 20, 2026
- Volume
- 18.45M sharesNov 20, 2026
- Market cap
- $918.5M HKDAt the close on Nov 20, 2026 · price × 412.8M shares outstanding
- 52-week range
- $2.17 – $77.00 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $46.70M HKDMedian day 5.22M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2565 · Home | $2.225 HKD | -0.195 (-8.1%) | 18,454,850 | $2.32 | $2.45 | $2.17 | $2.42 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2565 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.225 | -0.195 | -8.1% | $2.32 | $2.45 | $2.17 | 18,454,850 | |
| $2.42 | -0.43 | -15.1% | $2.83 | $2.895 | $2.42 | 22,498,300 | |
| $2.85 | -0.37 | -11.5% | $3.295 | $3.38 | $2.845 | 27,692,900 | |
| $3.22 | -0.03 | -0.9% | $3.625 | $3.795 | $3.22 | 59,264,350 | |
| $3.25 | -0.125 | -3.7% | $3.415 | $3.53 | $3.25 | 18,404,000 | |
| $3.375 | +0.115 | +3.5% | $3.22 | $3.44 | $3.21 | 20,727,450 | |
| $3.26 | -0.24 | -6.9% | $3.445 | $3.50 | $3.24 | 17,366,150 | |
| $3.50 | -0.20 | -5.4% | $3.525 | $3.695 | $3.425 | 32,160,500 | |
| $3.70 | +0.285 | +8.3% | $3.42 | $3.73 | $3.415 | 18,619,000 | |
| $3.415 | +0.045 | +1.3% | $3.155 | $3.76 | $3.155 | 37,598,500 | |
| $3.37 | +0.12 | +3.7% | $3.215 | $3.45 | $3.215 | 19,345,000 | |
| $3.25 | +0.175 | +5.7% | $3.165 | $3.345 | $3.05 | 18,503,200 | |
| $3.075 | -0.61 | -16.6% | $3.20 | $3.38 | $3.065 | 19,907,400 | |
| $3.685 | -0.40 | -9.8% | $4.075 | $4.155 | $3.665 | 16,835,200 | |
| $4.085 | +0.255 | +6.7% | $4.40 | $5.29 | $4.075 | 118,626,050 | |
| $3.83 | +0.25 | +7.0% | $3.58 | $4.04 | $3.555 | 22,008,450 | |
| $3.58 | +0.115 | +3.3% | $3.465 | $3.60 | $3.465 | 2,764,650 | |
| $3.465 | -0.06 | -1.7% | $3.525 | $3.715 | $3.425 | 4,893,800 | |
| $3.525 | +0.005 | +0.1% | $3.30 | $3.585 | $3.30 | 1,928,498 | |
| $3.52 | +0.12 | +3.5% | $3.70 | $3.70 | $3.20 | 4,786,250 | |
| $3.40 | -0.285 | -7.7% | $3.735 | $3.735 | $3.365 | 4,663,850 | |
| $3.685 | +0.015 | +0.4% | $3.80 | $3.82 | $3.655 | 2,455,850 | |
| $3.67 | -0.35 | -8.7% | $4.02 | $4.045 | $3.62 | 5,181,700 | |
| $4.02 | +0.035 | +0.9% | $4.025 | $4.515 | $3.99 | 8,528,600 | |
| $3.985 | -0.38 | -8.7% | $4.365 | $4.495 | $3.96 | 3,930,000 | |
| $4.365 | -0.255 | -5.5% | $4.64 | $4.665 | $4.36 | 3,606,850 | |
| $4.62 | +0.07 | +1.5% | $4.79 | $5.335 | $4.565 | 17,703,699 | |
| $4.55 | -0.14 | -3.0% | $4.75 | $4.785 | $4.55 | 1,518,000 | |
| $4.69 | -0.17 | -3.5% | $4.95 | $4.95 | $4.615 | 1,784,800 | |
| $4.86 | -0.185 | -3.7% | $5.25 | $5.25 | $4.83 | 2,626,300 | |
| $5.045 | -0.035 | -0.7% | $5.015 | $5.245 | $4.875 | 84,400 | |
| $5.08 | +0.18 | +3.7% | $4.89 | $5.105 | $4.89 | 88,200 | |
| $4.90 | +0.06 | +1.2% | $5.25 | $5.25 | $4.815 | 36,600 | |
| $4.84 | -0.37 | -7.1% | $4.50 | $5.08 | $4.50 | 248,550 | |
| $5.21 | +0.035 | +0.7% | $5.28 | $5.375 | $5.185 | 3,981,650 | |
| $5.175 | +0.11 | +2.2% | $5.20 | $5.42 | $5.08 | 4,366,550 | |
| $5.065 | -0.295 | -5.5% | $5.495 | $5.60 | $5.045 | 3,018,850 | |
| $5.36 | -0.155 | -2.8% | $5.51 | $5.515 | $5.33 | 93,100 | |
| $5.515 | -0.075 | -1.3% | $5.575 | $5.655 | $5.515 | 1,615,750 | |
| $5.59 | -0.06 | -1.1% | $5.735 | $5.74 | $5.57 | 3,024,300 | |
| $5.65 | -0.235 | -4.0% | $5.93 | $5.93 | $5.635 | 4,887,550 | |
| $5.885 | +0.09 | +1.6% | $5.805 | $6.08 | $5.785 | 12,320,100 | |
| $5.795 | +0.21 | +3.8% | $5.61 | $5.85 | $5.61 | 7,535,520 | |
| $5.585 | +0.035 | +0.6% | $5.625 | $5.78 | $5.51 | 5,259,450 | |
| $5.55 | -0.095 | -1.7% | $5.75 | $5.75 | $5.545 | 2,850,050 | |
| $5.645 | -0.145 | -2.5% | $5.855 | $5.855 | $5.645 | 2,614,750 | |
| $5.79 | -0.02 | -0.3% | $5.935 | $6.255 | $5.725 | 11,463,350 | |
| $5.81 | +0.19 | +3.4% | $5.62 | $5.825 | $5.475 | 9,897,050 | |
| $5.62 | +0.04 | +0.7% | $5.63 | $5.845 | $5.45 | 5,840,950 | |
| $5.58 | -0.06 | -1.1% | $5.61 | $5.795 | $5.55 | 3,988,350 | |
| $5.64 | +0.035 | +0.6% | $5.57 | $5.96 | $5.56 | 8,481,300 | |
| $5.605 | -0.13 | -2.3% | $5.735 | $5.735 | $5.57 | 2,368,500 | |
| $5.735 | +0.035 | +0.6% | $5.725 | $5.92 | $5.635 | 8,813,200 | |
| $5.70 | +0.115 | +2.1% | $5.90 | $6.06 | $5.60 | 15,029,200 | |
| $5.585 | +0.10 | +1.8% | $5.60 | $5.85 | $5.41 | 9,523,200 | |
| $5.485 | -0.01 | -0.2% | $5.57 | $5.57 | $5.44 | 1,986,950 | |
| $5.495 | -0.195 | -3.4% | $5.69 | $5.705 | $5.49 | 3,097,850 | |
| $5.69 | -0.185 | -3.1% | $5.945 | $5.945 | $5.68 | 3,757,250 | |
| $5.875 | -0.01 | -0.2% | $6.04 | $6.065 | $5.785 | 4,748,350 | |
| $5.885 | -0.405 | -6.4% | $6.01 | $6.28 | $5.885 | 8,466,300 | |
| $6.29 | +0.33 | +5.5% | $6.02 | $6.34 | $5.915 | 8,348,850 | |
| $5.96 | +0.085 | +1.4% | $5.925 | $6.11 | $5.75 | 5,377,950 | |
| $5.875 | -0.10 | -1.7% | $5.99 | $6.04 | $5.87 | 4,987,250 | |
| $5.975 | +0.075 | +1.3% | $6.215 | $6.45 | $5.975 | 13,109,750 |
- Ticker
- OTC:PGBIF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 15, 2026
Voluntary announcement successful inclusion of the group's core product paidakang (visepegenatide injection) into the 2026 NRDL
Latest news
Voluntary announcement successful inclusion of the group's core product paidakang (visepegenatide injection) into the 2026 NRDL
Nov 15, 2026
Closed $3.22 (-0.9%) on Nov 16, 2026
Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 26, 2026
Nov 11, 2026
Closed $3.38 (+3.5%) on Nov 12, 2026
Notice of the 2026 first extraordinary general meeting
Nov 11, 2026
Closed $3.38 (+3.5%) on Nov 12, 2026
(1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
Nov 11, 2026
Closed $3.38 (+3.5%) on Nov 12, 2026
Next Day Disclosure Return
Nov 10, 2026
Closed $3.26 (-6.9%) on Nov 11, 2026
Completion of placing of new h shares under general mandate
Nov 10, 2026
Closed $3.26 (-6.9%) on Nov 11, 2026
Cancellation of extraordinary general meeting and cancellation of book closure period
Nov 6, 2026
Closed $3.70 (+8.3%) on Nov 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 4, 2026
Closed $3.37 (+3.7%) on Nov 5, 2026
Placing of new h shares under general mandate
Nov 2, 2026
Closed $3.08 (-16.6%) on Nov 3, 2026
Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
Oct 23, 2026
Closed $3.53 (+0.1%) on Oct 26, 2026
PegBio Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 19 in all · newest Nov 15, 2026 · oldest 2026
Where PegBio Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2565 派格生物醫藥 · Home listing | HKEX | Hong Kong | HKD |
| OTC:PGBIF · This page | OTC | United States | USD |
| OTC:PGBCY | OTC | United States | USD |
Valuation
Price/book 2.9× against a median of 2.1×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $437.7M HKD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.83M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.66M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.3× | n/a | n/a | −146.4% | n/a | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| STCube, Inc. · KRX:052020 | US$117.7M | US$71.99M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Curacle Co., Ltd. · KRX:365270 | US$116.9M | US$99.81M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.21M | n/a | 59,054× | n/a | 3.6× | n/a | 0.0× | n/a |
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Median of the others | US$117.9M | US$70.61M | 15.0× | 2.1× | −229.6% | 0.0× | 0.97 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 101.80 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.44 · 1 analyst
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 29, 2025 | −1.4% |
| Quarter to Jun 30, 2021 | Aug 31, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new H shares Closed: HK$80.04M raised · HK$2.985 a share Use of proceeds: R&D of next-generation pipeline (PB-2309, APGP6, PB-2312) 60%; loan repayment and capital structure 20%; general corporate purposes and working capital 20% | Nov 10, 2026 | US$10.21M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | ||
| Gross profit | 0 | 0 | ||
| Research and development | 50.4M | 95.4M | 236.7M | 280.3M |
| Selling, general and administrative | 37.0M | 192.4M | 55.4M | 13.2M |
| Operating income | -205.9M | -280.9M | -277.5M | -318.5M |
| Depreciation and amortization | 3.74M | 2.20M | 3.44M | 4.39M |
| EBITDA | -202.2M | -278.6M | -274.0M | -314.1M |
| Interest expense | 2.78M | 6.82M | 11.6M | 159.0K |
| Income before tax | -208.5M | -283.4M | -279.2M | -306.3M |
| Net income | -208.4M | -283.2M | -279.0M | -306.4M |
| Earnings per share, basic | -0.53 | -0.73 | -0.72 | -0.79 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 467.5M | 28.4M | 77.1M | 60.3M |
| Short-term investments | 54.5M | 153.7M | 263.1M | 333.5M |
| Inventory | 873.0K | 0 | ||
| Current assets | 556.3M | 190.3M | 345.5M | 403.9M |
| Property, plant and equipment | 5.10M | 6.95M | ||
| Total assets | 599.2M | 218.4M | 368.1M | 437.5M |
| Accounts payable | 25.2M | 35.1M | 90.6M | 94.0M |
| Current liabilities | 141.1M | 157.7M | 165.0M | 125.7M |
| Total liabilities | 150.6M | 166.2M | 178.2M | 131.8M |
| Shareholders' equity | 448.5M | 52.2M | 189.9M | 300.0M |
| Shares outstanding | 391.1M | 386.0M | 386.0M | 386.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -151.9M | -183.4M | -233.3M | -171.4M |
| Capital spending | -3.66M | -1.08M | -617.0K | -3.21M |
| Free cash flow | -155.6M | -184.5M | -233.9M | -174.6M |
| Cash from investing | 114.4M | 101.6M | ||
| Cash from financing | 20.3M | 148.5M | ||
| Change in cash | 444.9M | -48.8M | 16.9M | -171.4M |
Filings
All 19 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | Oct 23, 2026 | Meeting notice | HKEX |
| (1) PROPOSED REMOVAL OF AUDITOR (2) PROPOSED APPOINTMENT OF AUDITOR (3) PROPOSED CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING AND (4) NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | Oct 23, 2026 | Meeting notice | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| 2026 Interim Report | Sep 23, 2026 | Interim report | HKEX |
| CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING | Sep 18, 2026 | Other filings | HKEX |
| PROPOSED CHANGE OF AUDITOR | Sep 18, 2026 | Management or board change | HKEX |
| VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT DRUG LIST ADJUSTMENT | Jun 29, 2026 | Operations update | HKEX |
| Next Day Disclosure Return | Jun 26, 2026 | Next day disclosure return | HKEX |
| LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | Jun 24, 2026 | List of directors | HKEX |
Cap table
Built by 6ix from PegBio Co., Ltd. Class H’s releases · as of Nov 10, 2026
- Common shares
- 412,815,390
- Fully diluted
- 412,815,390
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 412,815,390 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 412,815,390 |
Log in to ask 6ix AI your own questions about PegBio Co., Ltd.